Literature DB >> 7003455

Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil.

S E Vogl, R Lanham, B H Kaplan.   

Abstract

13 patients with advanced measurable colorectal cancer, having failed chemotherapy including fluorouracil, were treated on a weekly schedule with ICRF-159, 1.0 g/m2, and triazinate, 250 mg/m2. Only 1 patient had an objective partial remission, lasting 6 months. Toxicity was moderate, but acceptable. Since each of these drugs had been reported to have a 14-17% response rate in similar patient populations, the combination in the present schedule would appear to offer no benefit compared to the single agents, and cannot be recommended for further use in failure of 5-Fluorouracil therapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7003455     DOI: 10.1159/000225461

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  1 in total

1.  Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors.

Authors:  C L Vogel; E Gorowski; E Davila; M Eisenberger; J Kosinski; R P Agarwal; N Savaraj
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.